Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 8 to 70
Sponsor: Other
Protocol IDs: Lithium-5010, NCT01669369

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 382, NCT00691236

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 40 and over
Sponsor: Other
Protocol IDs: ISG/OS-2, 2011-001659-36, NCT01459484

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 21
Sponsor: Other
Protocol IDs: CCLG-EPSSG-NRSTS-2005, EU-20620, EUDRACT-2005-001139-31, UKCCSG-CTA-21275/0215/001/0001, CCLG-EpSSG-STS-2006-03, NCT00334854

Phase: Phase III
Type: Treatment
Status: Active
Age: 5 to 50
Sponsor: Other
Protocol IDs: CDR0000543987, FRE-FNCLCC-SARCOME-09-0603, FRE-FNCLCC-OS-2006, NOVARTIS-FRE-FNCLCC-SARCOME-09, CHUGAI-FRE-FNCLCC-SARCOME-09-0, EU-20729, EUDRACT-2006-00337727, NOVARTIS-FRE-FNCLCC-SARCOME-09-0603, CHUGAI-FRE-FNCLCC-SARCOME-09-0603, SARCOME 09/0603, NCT00470223

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: SCUSF-0703, MCC-0703, SCUSF 0703, NCT01132547

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 1 to 18
Sponsor: NCI, Other
Protocol IDs: CDR0000588655, COG-ACCL0431, ACCL0431, NCT00716976

Phase: Phase III
Type: Supportive care
Status: Active
Age: 1 to 21
Sponsor: Other
Protocol IDs: 06-08-367, NCT00726934

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BM016, NCT01091883

Phase: Phase III
Type: Diagnostic
Status: Active
Age: 2 to 18
Sponsor: Other
Protocol IDs: 1000010635, NCT00751920

Phase: Phase III
Type: Health services research, Treatment
Status: Approved-not yet active
Age: 6 to 18
Sponsor: Other
Protocol IDs: 1000018144, NCT01176981

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-154, NCT01223248

Phase: Phase III
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TH-CR-406/SARC021, NCT01440088

Phase: Phase III
Type: Screening
Status: Active
Age: 5 to 71
Sponsor: Other
Protocol IDs: CSET2011/1748, NCT01464086

Phase: Phase III
Type: Supportive care
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: GHRT01, NCT01479283

Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 09-0855-C, CIHR, NCT01506492

Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Lenze-2011, NCT01631175

Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7040-J081-301, NCT01677624

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 8 to 65
Sponsor: Other
Protocol IDs: 381, NCT00689195

Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 6 to 120
Sponsor: Other
Protocol IDs: HITHD-01, NCT01005043

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AVF4761s, 200911736, NCT01106872

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01412, 10-049, CDR0000680558, MSKCC-10049, U01CA069856, 8406, NCT01154452

Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 3 to 75
Sponsor: Other
Protocol IDs: NDV-HUJ-HMO-CTIL, NCT01174537

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 20
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: 100220, IND 59,056, NCT01222780

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441